Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Eloxx Pharmaceuticals Inc (EM) ELOX

Healthcare Biotechnology
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The... see more

Current News (EXPM:ELOX)

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

GlobeNewswire November 12, 2024

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

GlobeNewswire July 11, 2024

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

GlobeNewswire April 16, 2024

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

GlobeNewswire March 13, 2024

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

GlobeNewswire November 13, 2023

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

GlobeNewswire October 9, 2023

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire September 19, 2023

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

GlobeNewswire September 18, 2023

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

GlobeNewswire September 7, 2023
View More News ››

Opinion & Analysis (EXPM:ELOX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:ELOX)

Eloxx Pharmaceuticals, Inc. (OTC: ELOX): Navigating the Chal

http://beyondspx.com/2024/08/01/eloxx-pharmaceuticals-inc-otc-elox-navigating-the-challenges-of-rare-disease-drug-development/
MikeTester - August 2, 2024
View more Bullboard ››

Pelangio Exploration Inc.

Pelangio Exploration Inc.

Pelangio Exploration Inc., a mineral exploration company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts